For comparison of μ with PD-L1 staining, data were extracted from a total of 12 published clinical trials (n = 975 cancer patients) with data on clinical response by using a PD-L1 staining cutoff of ≥1% versus <1% and 1492 patients with a cutoff of ≥5% versus <5%. This evidence concerns the gene CD274 and cancer.